Profile Image

Dr Erin Harvey

Senior Research Assistant

School of Medicine and Public Health

Career Summary

Qualifications

  • PhD (Immunology & Microbiology), University of Newcastle
  • Bachelor of Biomedical Sciences, University of Newcastle
  • Bachelor of Biomedical Sciences (Hons), University of Newcastle

Keywords

  • testing

Fields of Research

Code Description Percentage
111299 Oncology and Carcinogenesis not elsewhere classified 100
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Journal article (10 outputs)

Year Citation Altmetrics Link
2020 Wang E, Wechsler ME, Tran TN, Heaney LG, Jones RC, Menzies-Gow AN, et al., 'Characterization of Severe Asthma Worldwide: Data From the International Severe Asthma Registry', Chest, 157 790-804 (2020) [C1]

© 2020 The Authors Background: Clinical characteristics of the international population with severe asthma are unknown. Intercountry comparisons are hindered by variable data coll... [more]

© 2020 The Authors Background: Clinical characteristics of the international population with severe asthma are unknown. Intercountry comparisons are hindered by variable data collection within regional and national severe asthma registries. We aimed to describe demographic and clinical characteristics of patients treated in severe asthma services in the United States, Europe, and the Asia-Pacific region. Methods: The International Severe Asthma Registry retrospectively and prospectively collected data in patients with severe asthma (= 18 years old), receiving Global Initiative for Asthma (GINA) Step 5 treatment or with severe asthma remaining uncontrolled at GINA Step 4. Baseline demographic and clinical data were collected from the United States, United Kingdom, South Korea, Italy, and the Severe Asthma Web-based Database registry (including Australia, Singapore, and New Zealand) from December 2014 to December 2017. Results: We included 4,990 patients. Mean (SD) age was 55.0 (15.9) years, and mean (SD) age at asthma onset was 30.7 (17.7) years. Patients were predominantly female (59.3%) and white (72.6%), had never smoked (60.5%), and were overweight or obese (70.4%); 34.9% were at GINA Step 5; and 57.2% had poorly controlled disease. A total of 51.1% of patients were receiving regular intermittent oral corticosteroids, and 25.4% were receiving biologics (72.6% for those at GINA Step 5). Mean (SD) exacerbation rate was 1.7 (2.7) per year. Intercountry variation was observed in clinical characteristics, prescribed treatments, and biomarker profiles. Conclusions: Using a common data set and definitions, this study describes severe asthma characteristics of a large patient cohort included in multiple severe asthma registries and identifies country differences. Whether these are related to underlying epidemiological factors, environmental factors, phenotypes, asthma management systems, treatment access, and/or cultural factors requires further study.

DOI 10.1016/j.chest.2019.10.053
Citations Scopus - 6Web of Science - 3
Co-authors Peter Gibson
2020 Harvey ES, Langton D, Katelaris C, Stevens S, Farah CS, Gillman A, et al., 'Mepolizumab effectiveness and identification of super-responders in severe asthma', EUROPEAN RESPIRATORY JOURNAL, 55 (2020) [C1]
DOI 10.1183/13993003.02420-2019
Citations Scopus - 4Web of Science - 3
Co-authors Vanessa Mcdonald, Peter Wark, Peter Gibson, Christopher Grainge
2019 Bulathsinhala L, Eleangovan N, Heaney LG, Menzies-Gow A, Gibson PG, Peters M, et al., 'Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study', Journal of Allergy and Clinical Immunology: In Practice, 7 578-588.e2 (2019) [C1]

© 2018 American Academy of Allergy, Asthma & Immunology Background: The lack of centralized data on severe asthma has resulted in a scarcity of information about the disease... [more]

© 2018 American Academy of Allergy, Asthma & Immunology Background: The lack of centralized data on severe asthma has resulted in a scarcity of information about the disease and its management. The development of a common data collection tool for the International Severe Asthma Registry (ISAR) will enable standardized data collection, subsequently enabling data interoperability. Objectives: To create a standardized list of variables for the first international registry for severe asthma via expert consensus. Methods: A modified Delphi process was used to reach consensus on a minimum set of variables to capture in ISAR: the core variables. The Delphi panel brought together 27 international experts in the field of severe asthma research. The process consisted of 3 iterative rounds. In each round, all Delphi panel members were issued an electronic ISAR Delphi workbook to complete and return to the ISAR Delphi administrator. Workbooks and result summaries were anonymously distributed by the Delphi administrator to all panel members at subsequent rounds. Finalization of the core variable list was facilitated by 2 face-to-face meetings. Results: Of the initial 747 selected variables, the Delphi panel reached a consensus on 95. The chosen variables will allow severe asthma to be assessed against patient demographics and medical history, patient-reported outcomes, diagnostic information, and clinical characteristics. Physician-reported outcomes such as nonadherence and information about treatment and management strategies will also be recorded. Conclusions: This is the first global attempt to generate an ISAR using a common set of core variables to ensure that data collected across all participating countries are standardized.

DOI 10.1016/j.jaip.2018.08.016
Citations Scopus - 11Web of Science - 14
Co-authors Peter Gibson
2019 Denton E, Hore-Lacy F, Radhakrishna N, Gilbert A, Tay TR, Lee J, et al., 'Severe Asthma Global Evaluation (SAGE): An Electronic Platform for Severe Asthma', Journal of Allergy and Clinical Immunology: In Practice, 7 1440-1449 (2019) [C1]

© 2019 American Academy of Allergy, Asthma & Immunology Severe asthma is complex and heterogeneous; ad hoc outpatient assessment can be suboptimal. Systematic evaluation imp... [more]

© 2019 American Academy of Allergy, Asthma & Immunology Severe asthma is complex and heterogeneous; ad hoc outpatient assessment can be suboptimal. Systematic evaluation improves outcomes and is recommended by international guidelines. Electronic templates improve physician performance and clinical processes, and may be useful in severe asthma systematic evaluation. We developed the Severe Asthma Global Evaluation (SAGE) electronic platform to streamline this process, via Research Electronic Data Capture (REDCap). It incorporates: a questionnaire battery for patient completion before clinical consultation; asthma and comorbidity modules; a clinical summary page in an asthma management module; a nurse educator module; a structured panel discussion record; and an automatically generated report incorporating all key data. SAGE incorporates 282 clinician input fields, with a typical consultation requiring completion of 169. To streamline the process SAGE contains 34 autocalculations and 20 decision support tools. It incorporates all 95 core variables of the International Severe Asthma Registry, with which it is directly compatible. SAGE improves symptom control and exacerbations in patients with difficult asthma. In conclusion, we developed and validated an electronic platform that facilitates a comprehensive but streamlined systematic evaluation of severe asthma that is available for free download via REDCap. Its use enhances management of patients with severe asthma and facilitates audit and international research collaboration.

DOI 10.1016/j.jaip.2019.02.042
Citations Scopus - 4Web of Science - 2
Co-authors Peter Gibson
2019 McDonald VM, Hiles SA, Godbout K, Harvey ES, Marks GB, Hew M, et al., 'Treatable traits can be identified in a severe asthma registry and predict future exacerbations', Respirology, 24 37-47 (2019) [C1]

© 2018 Asian Pacific Society of Respirology Background and objective: A new taxonomic and management approach, termed treatable traits, has been proposed for airway diseases inclu... [more]

© 2018 Asian Pacific Society of Respirology Background and objective: A new taxonomic and management approach, termed treatable traits, has been proposed for airway diseases including severe asthma. This study examined whether treatable traits could be identified using registry data and whether particular treatable traits were associated with future exacerbation risk. Methods: The Australasian Severe Asthma Web-Based Database (SAWD) enrolled 434 participants with severe asthma and a comparison group of 102 participants with non-severe asthma. Published treatable traits were mapped to registry data fields and their prevalence was described. Participants were characterized at baseline and every 6 months for 24 months. Results: In SAWD, 24 treatable traits were identified in three domains: pulmonary, extrapulmonary and behavioural/risk factors. Patients with severe asthma expressed more pulmonary and extrapulmonary treatable traits than non-severe asthma. Allergic sensitization, upper-airway disease, airflow limitation, eosinophilic inflammation and frequent exacerbations were common in severe asthma. Ten traits predicted exacerbation risk; among the strongest were being prone to exacerbations, depression, inhaler device polypharmacy, vocal cord dysfunction and obstructive sleep apnoea. Conclusion: Treatable traits can be assessed using a severe asthma registry. In severe asthma, patients express more treatable traits than non-severe asthma. Traits may be associated with future asthma exacerbation risk demonstrating the clinical utility of assessing treatable traits.

DOI 10.1111/resp.13389
Citations Scopus - 30Web of Science - 25
Co-authors Vanessa Mcdonald, Peter Gibson, Sarah Hiles, Peter Wark
2018 Hiles SA, Harvey ES, McDonald VM, Peters M, Bardin P, Reynolds PN, Upham JW, 'Working while unwell: Workplace impairment in people with severe asthma', CLINICAL AND EXPERIMENTAL ALLERGY, 48 650-662 (2018)
DOI 10.1111/cea.13153
Citations Scopus - 20Web of Science - 18
Co-authors Sarah Hiles, Vanessa Mcdonald, Peter Wark, Peter Gibson
2017 Wang G, Wang F, Gibson PG, Guo M, Zhang WJ, Gao P, et al., 'Severe and uncontrolled asthma in China: A cross-sectional survey from the Australasian Severe Asthma Network', Journal of Thoracic Disease, 9 1333-1344 (2017) [C1]
DOI 10.21037/jtd.2017.04.74
Citations Scopus - 11Web of Science - 11
Co-authors Peter Gibson
2011 Au GG, Beagley LG, Haley ES, Barry RD, Shafren DR, 'Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18', Virology Journal, 8 1-6 (2011) [C1]
DOI 10.1186/1743-422x-8-22
Citations Scopus - 19Web of Science - 21
Co-authors Gough Au
2009 Haley ES, Au GG, Carlton BR, Barry RD, Shafren DR, 'Regional administration of oncolytic Echovirus 1 as a novel therapy for the peritoneal dissemination of gastric cancer', Journal of Molecular Medicine, 87 385-399 (2009) [C1]
DOI 10.1007/s00109-008-0433-0
Citations Scopus - 13Web of Science - 11
Co-authors Gough Au
2004 Shafren DR, Au GG, Nguyen T, Barry RD, Hansbro NG, Harvey ES, et al., 'Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, Coxsackievirus A21', Clinical Cancer Research, 10 53-60 (2004) [C1]
DOI 10.1158/1078-0432.CCR-0690-3
Citations Scopus - 77Web of Science - 82
Co-authors Nicole Hansbro, Gough Au
Show 7 more journal articles

Conference (4 outputs)

Year Citation Altmetrics Link
2019 Harvey E, Langton DL, Powell H, Gibson PG, 'Clinical response to mepolizumab in patients with severe eosinophilic asthma', EUROPEAN RESPIRATORY JOURNAL, Madrid, SPAIN (2019)
DOI 10.1183/13993003.congress-2019.PA541
Citations Web of Science - 2
Co-authors Peter Gibson
2019 Harvey E, Langton D, Powell H, Gibson P, 'CLINICAL RESPONSE TO MEPOLIZUMAB IN PATIENTS WITH SEVERE EOSINOPHILIC ASTHMA', RESPIROLOGY (2019)
Co-authors Peter Gibson
2018 McDonald VM, Hiles SA, Godbout K, Harvey ES, Marks GB, Hew M, et al., 'Identification of treatable traits in a severe asthma registry: prevalence and exacerbation predictors', EUROPEAN RESPIRATORY JOURNAL, Paris, FRANCE (2018)
DOI 10.1183/13993003.congress-2018.PA5043
Co-authors Peter Wark, Vanessa Mcdonald, Sarah Hiles, Peter Gibson
2017 Wang G, Gibson PG, Wang F, Guo M, Zhang W, Gao P, et al., 'Severe Asthma, Uncontrolled Asthma, And The Use Of Triple Controller Therapy For Asthma In China', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Washington, DC (2017)
Co-authors Peter Gibson
Show 1 more conference
Edit

Grants and Funding

Summary

Number of grants 1
Total funding $10,000

Click on a grant title below to expand the full details for that specific grant.


20201 grants / $10,000

Investigating the health effects of bushfire smoke exposure, specifically on people with asthma, including pregnant women with asthma, and their children$10,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Conjoint Professor Peter Gibson, Doctor Vanessa Murphy, Professor Vanessa McDonald, Doctor Adam Collison, Conjoint Associate Professor Anne Vertigan, Doctor Megan Jensen, Doctor Dennis Thomas, Associate Professor Jay Horvat, Professor Maralyn Foureur, Professor Leigh Kinsman, Associate Professor Liz Holliday, Doctor Erin Harvey, Ms Alycia Jacob, Professor Joerg Mattes, Graeme Zosky, Wilfried Karmaus, Michele Goldman, Dr Craig Dalton
Scheme Research Grant
Role Investigator
Funding Start 2020
Funding Finish 2020
GNo G2000414
Type Of Funding C3120 - Aust Philanthropy
Category 3120
UON Y
Edit

Dr Erin Harvey

Position

Senior Research Assistant
Department of Respiratory & Sleep Medicine
School of Medicine and Public Health
Faculty of Health and Medicine

Contact Details

Email erin.harvey@newcastle.edu.au
Phone (02) 4042 0099
Fax (02) 4042 0046

Office

Building Hunter Medical Research Institute
Location Level 2 West Wing, Hunter Medical Research Institute, Lot 1 Kookaburra Circuit New Lambton Heights 2305

,
Edit